HY

REC'T T/PTO 21 FEB 2006

I hereby certify that this corresponde being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 335374783 US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 450 Alexandria, VA 22313-1450, on the date shown below.

Dated: February 21, 2006

Signature:

Lio qua halos

Patent
Docket No. 254082000600, ,
Client Reference No. 16958/US/03

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Abdullah I. HAJ-YEHIA et al.

Serial No.: 10/535,620

Int'l Application No. PCT/IL2003/000986

Int'l Filing Date: November 21, 2003

For: BETA-BLOCKERS HAVING

ANTIOXIDANT AND NO-DONOR

**ACTIVITY** 

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

	With	the application; accordingly, no fee or separate requirements are required.
	Befor	e the mailing of a first Office Action after the filing of a Request for Continued
	Exam	ination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1)	has been provided.
$\boxtimes$	Withi	n three months of the application filing date or before mailing of a first Office Action
	on the	merits; accordingly, no fee or separate requirements are required. However, if
	applic	able, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After	receipt of a first Office Action on the merits but before mailing of a final Office Action
	or No	tice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
		this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
		believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

Patent
Docket No. 254082000600
Client Reference No. 16958/US/03

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 254082000600.

Dated: February 21, 2006

· Respectfully submitted,

Kimberly A. Bolin

Registration No.: 44,546

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304-1018

(650) 813-5740

App U.S. Patent and Trade no persons are required to respond to a collection of informa.

for use through 07/31/2006. OMB 0651-0031 office; U.S. DEPARTMENT OF COMMERCE chless it contains a valid OMB control number.

Under the Paperwork Reduction Act of

Substitute for form 1449/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/535,620				
Filing Date	(Intl.) 21/11/2003				
First Named Inventor	HAJ-YEHIA, Abdullah Ibrahim				
Art Unit	Not Yet Assigned				
Examiner Name	Not Yet Assigned				
Attorney Docket Number	25408-20006.00				

	U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	1.	<sup>US-</sup> 6,121,328	19/09/2000	Weglicki William B	9-19				
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
	_	US-							
		US-							
		US-							
		US-							
		US-							
		US-							
(6)		US-							
		US-							
		US-							
		US-							
		US-							

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages					
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>				
	2.	WO 00/61541	19/10/2000	Nicox SA	10-19					
	3.	WO 01/35961	25/05/2001	Univ Boston	05-25					
	4.	WO 02/092078	21/11/2002	Tyabji Ziauddin Z	11-21					
	5.	WO 03/088961	30/10/2003							
	6.	10. WO 10. WO 98/21193	05/22/1998	Nicox SA	05-22					
	7.	WO 98/42661	10/01/1998	Yissum Res Dev Co						

Examiner	Date	<del></del>
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (07-05)

App for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trad Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/535,620				
Filing Date	(Intl.) 21/11/2003				
First Named Inventor	HAJ-YEHIA, Abdullah Ibrahim				
Art Unit	Not Yet Assigned				
Examiner Name	Not Yet Assigned				
Attorney Docket Number	25408-20006.00				

		U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
		Number-Kind Code <sup>2 (f known)</sup> US-			· · · · · · · · · · · · · · · · · · ·					
		US-								
		US-								
		US-								
-		US-								
		US-								
		US-								
		US-		440						
	<del> </del>	US-								
	<del></del>	US-								
		US-								
		US-								
		US-								
		US-								
		US-								
-		US-	<del>                                     </del>	<u></u>	<del></del>					
		US-								
	<del> </del>	US-								
<del></del>	<del>                                     </del>	US-								

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	1
	8.	WO 99/37616	0729/1999	Aenggaard Erik Emil	07-29	
						L
						L
	1					

Examiner		Date	
Signature	·	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

An analysis of for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Tra

Office; U.S. DEPARTMENT OF COMMERCE
Unless it contains a valid OMB control number.

	te for form 1449/PTO	gao.ioji / A	, no percent a		Complete if Known	
Subsulu	te 101 101111 1445/F10			Application Number	10/535,620	
INF	ORMATION	N DIS	CLOSURE	Filing Date	(Intl.) 21/11/2003	
STATEMENT BY APPLICANT				First Named Inventor	HAJ-YEHIA, Abdullah Ibrahim	
	(Use as many sh	oote se n	acassan/l	Art Unit	Not Yet Assigned	
	(USE as many sn	10013 d3 11	ecessary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	25408-20006.00	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	9.	Marton Z et al; 'Scavenger effect ofused cardiovascular drugs'; Journal of cardiovascular pharmacology 2001 United States, vol.38, no.5, 2001, 745-753	
	10	Mizuno K et al; 'Neuroprotective effect andoxide donative action'; Inves. Ophthal. & Visual Sc., Asso. for Res. in Vision and, US, vol42, no. 3; Mar 2001; 688-694	
	11.	Mousa S A et al; 'Myocardial anti-ischemic of beta-adrenoceptor blockers'; Inter. Journal of Clinical Phar. Therapy and Toxicology, vol.30, no. 3, 1992, 103-106	
	12.	Reddy Doodipala Samba et al; 'Comparative antioxidant effects ventricular microsomal membranes'; Methods & Findings in Experi. & Clini. Pharm., vol. 18, no. 9, 1996, 559-567	
			1
			·

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.